Recludix Pharma Enters into a Strategic Collaboration with Sanofi to Advance Novel Oral STAT6 Inhibitor in Multiple Immunological and Inflammatory Indications

Recludix Pharma, Inc., a leading company in the discovery of inhibitors for challenging targets in inflammatory disease and cancer, has announced a strategic collaboration with Sanofi US (NASDAQ: SNY) to develop and market innovative oral small molecule STAT6 inhibitors. The goal of this collaboration is to advance the development of a preclinical oral STAT6 inhibitor for patients suffering from..